Arrowhead Pharmaceuticals Cash Flow Statement

Financials in millions USD. Fiscal year is October - September.

Millions USD. Fiscal year is Oct - Sep.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep '25 Sep 30, 2025	Sep '24 Sep 30, 2024	Sep '23 Sep 30, 2023	Sep '22 Sep 30, 2022	Sep '21 Sep 30, 2021
Net Income	-1.63	-599.49	-205.28	-176.06	-140.85
Depreciation & Amortization	23.93	18.6	12.49	10.42	8.27
Loss (Gain) From Sale of Investments	-	0.08	-	4.43	-1.71
Stock-Based Compensation	63.37	73.97	78.13	120.89	76.67
Other Operating Activities	112.12	18.91	12.31	2.48	0.27
Change in Accounts Receivable	-56.97	-	1.41	8.85	-9.41
Change in Accounts Payable	6.29	-5.54	33	-6.59	2.63
Change in Unearned Revenue	2.4	-0.87	-129.18	-112.5	223.26
Change in Other Net Operating Assets	30.05	31.49	43.23	11.95	12.19
Operating Cash Flow	179.55	-462.85	-153.89	-136.13	171.31
Capital Expenditures	-22.67	-141.47	-176.74	-52.78	-23.57
Investment in Securities	-106.63	-278.6	80.58	47.36	-118.11
Investing Cash Flow	-129.29	-420.07	-96.16	-5.42	-141.68
Short-Term Debt Issued	10.26	-	-	-	-
Long-Term Debt Issued	-	392	-	-	-
Total Debt Issued	10.26	392	-	-	-
Long-Term Debt Repaid	-201.63	-	-	-	-
Net Debt Issued (Repaid)	-191.37	392	-	-	-
Issuance of Common Stock	245.37	431.65	3.05	5.19	11.31
Other Financing Activities	20	46.87	250	60	-
Financing Cash Flow	74.01	870.52	253.05	65.19	11.31
Foreign Exchange Rate Adjustments	-0.4	4.2	-0.12	-0.07	-0.09
Net Cash Flow	123.86	-8.21	2.89	-76.43	40.85
Free Cash Flow	156.89	-604.32	-330.63	-188.91	147.75
Free Cash Flow Margin	18.92%	-17018.31%	-137.34%	-77.67%	106.84%
Free Cash Flow Per Share	1.17	-5.04	-3.10	-1.79	1.42
Cash Interest Paid	0.02	-	-	-	-
Cash Income Tax Paid	-0.81	3.74	-	0	0
Levered Free Cash Flow	96.15	-440.13	-251.42	-60.64	63
Unlevered Free Cash Flow	152	-419.91	-239.96	-60.64	63
Change in Working Capital	-18.24	25.09	-51.55	-98.29	228.66

Source: S&P Global Market Intelligence. Standard template. Financial Sources.